These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 18326970)

  • 1. Bayesian meta-analysis of tissue angiotensin-converting enzyme inhibitors for reduction of adverse cardiovascular events in patients with diabetes mellitus and preserved left ventricular function.
    Lang CD; Arora RR; Saha SA; Molnar J
    J Cardiometab Syndr; 2008; 3(1):45-52. PubMed ID: 18326970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue ACE inhibitors for secondary prevention of cardiovascular disease in patients with preserved left ventricular function: a pooled meta-analysis of randomized placebo-controlled trials.
    Saha SA; Molnar J; Arora RR
    J Cardiovasc Pharmacol Ther; 2007 Sep; 12(3):192-204. PubMed ID: 17875946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
    Saha SA; Molnar J; Arora RR
    Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials.
    Dagenais GR; Pogue J; Fox K; Simoons ML; Yusuf S
    Lancet; 2006 Aug; 368(9535):581-8. PubMed ID: 16905022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
    Teo K; Yusuf S; Sleight P; Anderson C; Mookadam F; Ramos B; Hilbrich L; Pogue J; Schumacher H;
    Am Heart J; 2004 Jul; 148(1):52-61. PubMed ID: 15215792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis.
    Yusuf S
    Am J Cardiol; 2002 Jan; 89(2A):18A-25A; discussion 25A-26A. PubMed ID: 11835907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Rationale, characteristics and study design of PREAMI (Perindopril and Remodelling in the Elderly with Acute Myocardial Infraction)].
    Magrini G; Nicolosi GL; Chiariello M; Ferrari R; Remme P; Tavazzi L
    Ital Heart J; 2005 Nov; 6 Suppl 7():14S-23S. PubMed ID: 16485513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials.
    Xie X; Liu Y; Perkovic V; Li X; Ninomiya T; Hou W; Zhao N; Liu L; Lv J; Zhang H; Wang H
    Am J Kidney Dis; 2016 May; 67(5):728-41. PubMed ID: 26597926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue angiotensin-converting enzyme inhibitors: are they more effective than serum angiotensin-converting enzyme inhibitors?
    Shah AD; Arora RR
    Clin Cardiol; 2005 Dec; 28(12):551-5. PubMed ID: 16405197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ramipril: a review of its use in the prevention of cardiovascular outcomes.
    Warner GT; Perry CM
    Drugs; 2002; 62(9):1381-405. PubMed ID: 12076194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin II and trials of cardiovascular outcomes.
    Sleight P
    Am J Cardiol; 2002 Jan; 89(2A):11A-16A; discussion 16A-17A. PubMed ID: 11835905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ACE-inhibitors versus angiotensin receptor blockers for prevention of events in cardiovascular patients without heart failure - A network meta-analysis.
    Ricci F; Di Castelnuovo A; Savarese G; Perrone Filardi P; De Caterina R
    Int J Cardiol; 2016 Aug; 217():128-34. PubMed ID: 27179902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE.
    Gerstein HC
    Diabetes Metab Res Rev; 2002; 18 Suppl 3():S82-5. PubMed ID: 12324991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis.
    Cheng J; Zhang W; Zhang X; Han F; Li X; He X; Li Q; Chen J
    JAMA Intern Med; 2014 May; 174(5):773-85. PubMed ID: 24687000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Not all angiotensin-converting enzyme inhibitors are equal: focus on ramipril and perindopril.
    Dinicolantonio JJ; Lavie CJ; O'Keefe JH
    Postgrad Med; 2013 Jul; 125(4):154-68. PubMed ID: 23933903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renin angiotensin system inhibitors for patients with stable coronary artery disease without heart failure: systematic review and meta-analysis of randomized trials.
    Bangalore S; Fakheri R; Wandel S; Toklu B; Wandel J; Messerli FH
    BMJ; 2017 Jan; 356():j4. PubMed ID: 28104622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials.
    Danchin N; Cucherat M; Thuillez C; Durand E; Kadri Z; Steg PG
    Arch Intern Med; 2006 Apr; 166(7):787-96. PubMed ID: 16606817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The HOPE Study (Heart Outcomes Prevention Evaluation).
    Sleight P
    J Renin Angiotensin Aldosterone Syst; 2000 Mar; 1(1):18-20. PubMed ID: 11967789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular protection with ace inhibitors--more HOPE for EUROPA?
    Boos CJ
    Med Sci Monit; 2004 Dec; 10(12):SR23-8. PubMed ID: 15567997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spotlight on ramipril in the prevention of cardiovascular outcomes.
    Warner GT; Perry CM
    Am J Cardiovasc Drugs; 2003; 3(2):113-6. PubMed ID: 14727938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.